At the news
? NEUTRALIMPACT 2/10 CLUSTER filed Jun 8, 2026 at 16:36 ET
Two Keros Therapeutics directors sold a combined $56K in open-market sales on June 4, 2026, following a round of non-cash stock grants to the same directors on June 3. The sales are trivial relative to the $204M market cap (0.03%) and are likely liquidity-driven after the grants, not a bearish signal. The cluster is not amplified by any cross-filing context (no earnings, offering, or late-filing events nearby).
- Two directors (Seth Alpna and Knowles Julius) each sold 2,625 shares on June 4, 2026, at ~$10.72-$10.73, totaling $56,306.
- Both sales occurred one day after each director received non-cash stock grants (7,433 and 7,142 shares respectively) on June 3, 2026.
- Total sale value of $56K represents only 0.03% of KROS's $204M market cap, well below the 0.1% materiality threshold.
- No C-suite executives participated in the sales; only two directors sold.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access